Search
Olinciguat
go.drugbank.com/drugs/DB15238InvestigationalOlinciguat is under investigation in clinical trial NCT03892499 (A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator
Mezigdomide
go.drugbank.com/drugs/DB17584InvestigationalMezigdomide is under investigation in clinical trial NCT05372354 (A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants
RGX-111
go.drugbank.com/drugs/DB17632InvestigationalRGX-111 is an adeno-associated virus vector AAV9 designed to deliver the α-L-iduronidase (IDUA) gene.
Tulisokibart
go.drugbank.com/drugs/DB18719InvestigationalPRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15.
Metribolone
go.drugbank.com/drugs/DB02998ExperimentalIt binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.
Synonyms: 17-beta-Hydroxy-17-methylestra-4,9,11-trien-3-one3-methyl-benzene-1,2-diol
go.drugbank.com/drugs/DB03454ExperimentalThis compound belongs to the catechols. These are compounds containing a 1,2-benzenediol moeity. 3-methyl-benzene-1,2-diol targets the protein biphenyl-2,3-diol 1,2-dioxygenase.
SOBI-003
go.drugbank.com/drugs/DB15451InvestigationalIt is under investigation in clinical trial NCT03811028 (A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients).
Pegcrisantaspase
go.drugbank.com/drugs/DB16281InvestigationalFollowing Hypersensitivity to Pegaspargase (Oncaspar)).
AAV1-FS344
go.drugbank.com/drugs/DB17855InvestigationalAAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.
Ormeloxifene
go.drugbank.com/drugs/DB13310Experimental[A251470] Similar to other selective estrogen receptor modulators (SERMs), ormeloxifene has estrogenic activity in the vagina, bone, cardiovascular, and central nervous system tissues, and anti-estrogenic … [A251475] The use of levormeloxifene for the treatment of reduced bone turnover and the prevention of atherosclerosis has been evaluated; however, drug development was discontinued due to adverse events